What You Should Know
Verily Health Inc. has secured a strategic equity investment from NVIDIA, extending its fundraising momentum following its corporate restructuring and initial $300 million funding round in early 2026.CU Healthcare Innovation Fund II, LP committed an additional follow-on investment, joining a capitalization syndicate that includes Alphabet (as a minority stakeholder), Series X Capital, and UCHealth.Directly accelerates commercial deployment of the Verily Pre Platform, the
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Salesforce Unveils Agentic Life Sciences Suite to Turn Reactive Operations into Compliant-by-Design Intelligence
What You Should Know
Salesforce announced three major enterprise artificial intelligence additions to its life sciences portfolio: Regulated Content Management (RCM), Command Center for Life Sciences, and Life Sciences MCP (Model Context Protocol).Focuses on widespread industry inefficiencies, targeting scenarios where half of all pharmaceutical drug launches fail to meet pre-launch projections and commercial teams spend months waiting for manual Medical, Legal, and Regulatory (MLR)
Read More
Weave Bio and Takeda Deploy AI Regulatory Automation Across 14 Global Programs
What You Should Know
AI-native regulatory software company Weave Bio announced a major enterprise collaboration with global biopharma leader Takeda to deploy its regulatory automation platform across 14 active drug development programs in multiple global markets.The collaboration directly addresses the heavy administrative bottleneck of regulatory dossier authoring, which has historically trapped critical scientific data inside static, hard-to-maintain document repositories.The system handled
Read More
Labcorp Redesigns Global Trial Connect to Streamline Sponsor and Investigator Workflows
What You Should Know
Labcorp launched major digital enhancements to Labcorp Global Trial Connect™, redesigning both the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences.Co-developed and guided by direct product testing and feedback from more than 80 biopharma sponsors and 100 clinical investigator sites worldwide.Features embedded in-portal kit ordering that cuts manual data entry by 75% while standardizing inventory tracking and supply replenishment.Introduces a unified Study
Read More
Built on Precious Metals: Advancing Medical Devices Through Material Precision
In medical applications, performance begins at the material level. Whether used in implantable devices, diagnostic tools, or surgical instruments, materials are required to meet stringent standards for biocompatibility and structural integrity. Consistent material properties enable stable processing and component performance, forming a reliable foundation for downstream device manufacturing and validation.
As healthcare systems become more connected, medical devices are expected to operate
Read More
Memorial Hermann Makes Strategic Investment in PartsSource to Optimize Medical Equipment Lifecycles
What You Should Know
PartsSource, a clinical technology performance and asset management platform, announced a strategic investment from Memorial Hermann Health System, one of the largest non-profit health systems in Southeast Texas.PartsSource provides an enterprise operating system for Healthcare Technology Management (HTM) that unifies medical equipment parts procurement, maintenance service, contract management, asset intelligence, and clinical engineering workforce capacity.The platform
Read More
Roche Receives FDA Clearance for Elecsys pTau217, First Single-Biomarker Alzheimer’s Blood Test for Primary and Specialty Care
What You Should Know
The U.S. Food and Drug Administration (FDA) has cleared Roche’s Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, developed in strategic collaboration with Eli Lilly and Company.It is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology associated with Alzheimer’s disease using the exact same validated clinical cutoffs across both primary care and specialty neurology settings.The test is
Read More
The Premium Programmatic Imperative: Why Pharma’s HCP Engagement Strategy Needs a Serious Upgrade
When did "we believe we reached physicians" become an acceptable standard for a billion-dollar industry? Somewhere along the way, pharma marketing made peace with probabilistic targeting, inferred identities, and impression counts that looked impressive but proved little. The industry didn't lower its clinical standards. It just never applied them to its media buying.
That disconnect is no longer sustainable. And it's not a media buying problem. It's a structural one.
The Illusion of
Read More
Bristol Myers Squibb Partners with Chai Discovery for AI Antibody Design
What You Should Know
Chai Discovery announced a strategic biopharmaceutical collaboration with Bristol Myers Squibb (BMS) to advance the discovery and engineering of therapeutic antibodies using artificial intelligence.Bristol Myers Squibb will integrate Chai’s proprietary molecular folding and de novo design models across its drug discovery portfolio to power an AI-driven, continuously learning discovery system.Chai Discovery’s platform acts as a computer-aided design (CAD) suite for
Read More
DCAI and Corti Launch Sovereign AI Control Layer on Gefion Supercomputer
What You Should Know
The Danish Center for AI Innovation (DCAI) and clinical AI lab Corti have launched Corti Models, a governed, model-agnostic infrastructure layer providing European enterprises with sovereign control over AI deployments, data security, and compliance.The platform provides an OpenAI-compatible API supporting sovereign cloud and on-premises environments, allowing organizations to route workloads to leading foundation models without rewriting existing SDK integrations or
Read More
